Shares of Moderna Inc. MRNA, 4.02% were up 2.9% in premarket trading on Thursday after the company again reminded investors that the Phase 3 clinical trial for its COVID-19 vaccine candidate is fully enrolled as part of its third-quarter earnings announcement. It also said it is “actively preparing for the launch” of its COVID-19 vaccine. Moderna is a preclinical company, meaning it does not yet have an authorized or approved product available on the market. It is developing several mRNA-based vaccines, including one for the coronavirus. The company said its research and development expenses have nearly tripled to $344.5 million in the third quarter of 2020, primarily due to R&D costs for its experimental COVID-19 vaccine, compared with $119.6 million in the same quarter a year ago. Moderna said it plans to conduct two interim analyses for the late-stage trial of the vaccine. Moderna’s stock has gained 236.1% so far this year, while the S&P 500 SPX, 0.66% is up 1.2%.
About The Author
Too many f***ing liberties taken away from us’: former Oasis songwriter Noel Gallagher rejects UK mask mandate
September 16, 2020
October 28, 2020
Judge rules Ghislaine Maxwell details are too “sensational and impure” to be disclosed to the public
March 20, 2021